Sucroferric oxyhydroxide
Sucroferric oxyhydroxide is an iron-based phosphate binder used to control phosphorus levels in adults with chronic kidney disease (CKD) on dialysis. It is a non-calcium, non-aluminum phosphate binder that was approved by the Food and Drug Administration (FDA) in 2013.
Pharmacology[edit]
Sucroferric oxyhydroxide is a complex of iron(III)-oxyhydroxide, sucrose, and starches. It works by binding to dietary phosphate in the gastrointestinal tract, thereby reducing phosphate absorption and lowering serum phosphate levels in patients with CKD.
Clinical Use[edit]
Sucroferric oxyhydroxide is used to control serum phosphorus levels in patients with CKD on dialysis. High serum phosphorus levels, or hyperphosphatemia, is a common problem in patients with CKD and can lead to serious complications such as bone disease and cardiovascular disease.
Side Effects[edit]
The most common side effects of sucroferric oxyhydroxide include diarrhea, nausea, and vomiting. Other side effects may include constipation, abdominal pain, and hyperphosphatemia.
Dosage[edit]
The dosage of sucroferric oxyhydroxide is individualized based on the patient's serum phosphorus levels. The starting dose is usually 1.5 g/day, divided into three doses, taken with meals.
See Also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
